Pharmacoeconomics of infection in the intensive care unit;Farmacoeconomía de la infección en la Unidad de Cuidados Intensivos

Revista Espanola de Quimioterapia

Volumn 21, Issue SPEC. ISS. 1, 2008, Pages 26-34

  Grau, Santiago ^a   Alvarez Lerma F ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Antibiotic policy; Early antibiotic treatment; ICU; Infection; Pharmacoeconomic studies; Pharmacoeconomics

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; COST OF ILLNESS; DRUG COST; DRUG UTILIZATION; EARLY INTERVENTION; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MEDICATION ERROR; MORTALITY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COSTS AND COST ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; INTENSIVE CARE UNITS;

EID: 54949123422     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Chalfin DB. Pharmacoeconomic investigations in intensive care. Curr Opin Crit Care 2001;7:460-3.
2. Gutiérrez Zufiaurre MN, García Rodríguez JA. Encuesta multicéntrica nacional sobre utilización de antibióticos intravenosos. Rev Esp Quimioterap 2006;19:349-56.
3. Birmingham MC, Hasset JM, Schentag JJ, Paladino JA. Assessing antibacterial pharmacoeconomics in the intensive care unit. Pharmacoeconomics 1997;12:637-47.
4. Shorr AF. Epidemiology and economic impact of methicillin-resistant Staphylococcus aureus. Pharmacoeconomics 2007;25: 751-68.
5. Saint S, Veenstra DL, Lipsky BA. The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful? Infect Control Hosp Epidemiol 2000; 21:375-80.
6. Veenstra DL, Saint S, Sullivan S. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999;282:554-60.
7. Pittet D, Wenzel RP. Nosocomial bloodstream infections in the critically ill. JAMA 1994;272:1819-20.
8. Arnow PM, Quimosing EM, Beach M. Consequences of intravascular cateter sepsis. Clin Infect Dis 1993;16:778-84.
9. Shannon RP, Patel B, Cummins D, Shannon AH, Ganguli G, Lu Y. Economics of central line-associated bloodstream infections. Am J Med Qual 2006;21(Suppl. 6):7S-16.
10. Higuera F, Rangel-Frausto MS, Rosenthal VD, Martínez Soto J, Castañón J, Franco G, et al. Attributable cost and length of stay for patients with central venous catheter-associated bloodstream infection in Mexico city intensive care units: a prospective, matched analysis. Infect Control Hosp Epidemiol 2007;28:31-5.
11. Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski. The costs of septic sindromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med 2003;29:1464-71.
12. Íñigo J, Sendra JM, Díaz R, Bouza C, Sarría-Santamera A. Epidemiologia y costes de la sepsis grave en Madrid. Estudio de altas hospitalarias. Med Intensiva 2006;30:197-203.
13. McEachern R, Campbell GD. Hospital-acquired pneumonia: epidemiology, etiology and treatment. Infect Dis Clin North Am 1998;12:761-79.
14. George DL. Epidemiology of nosocomial pneumonia in intensive care unit patients. Clin Chest Med 1995;1:29-44.
15. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, et al. Outcome and attibutable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003;31:1312-7.
16. Cocanour CS, Ostrosky-Zeichner L, Peninger M, Garbade D, Tidemann T, Domonoske BD, et al. Cost of a ventilator-associated pneumonia in a shock trauma intensive care unit. Surg Infect (Larchmt) 2005;6:65-72.
17. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77.
18. Jain M, Miller L, Belt, D, King D, Berwick DM. Decline in ICU adverse events, nosocomial infections and cost through a quality improvement iniciative focusing on teamwork and culture change. Qual Saf Health Care 2006;15:235-9.
19. Clancy M, Graqepler A, Wilson M, Douglas I, Johnson J, Savor Price C. Active screening in high-risk units is an effective and cost-avoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospital. Infect Control Hosp Epidemiol 2006; 27:1009-17.
20. Meyer E, Buttler J, Schneider C, Strehl E, Schroeren-Boersch B, Gastmeier P, et al. Modified guidelines impact on antibiotic use and costs: duration of treatment for pneumonia in a neurosurgical ICU is reduced. J Antimicrob Chemother 2007;59:1148-54.
21. Hatler C, Mast D, Corderella J, Mitchell G, Howard K, Aragón J, et al. Using evidence and process improvement strategies to enhance healthcare outcomes for the critically ill: a pilot Project. Am J Crit Care 2006;15:549-55.
22. Thureen PJ, Reiter PD, Gresores A, Stolpman NM, Kawato K, Hall DM. Once verus twice-daily gentamicin dosing in neonates ≥34 weeks' gestation: cost-effectiveness analyses. Pediatrics 1999; 103:594-8.
23. Micek ST, Roubinian N, Heuring T, Bode M, Williams J, Harrison C, et al. A before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 2006; 34:2707-13.
24. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving sepsis campaign guidelines for management of severe sepsis and sepsis shock. Crit Care Med 2004;32:858-73.
25. Shorr AF, Micek ST, Jackson WL Jr, Kollef MH. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs? Crit Care Med 2007;35:1257-62.
26. Nuchols TK, Paddock SM, Bower AG, Rothschild JM, Fairbanks RJ, Carlson B, et al. Costs of intravenous adverse drug events in academic and nonacademic intensive care units. Med Care 2008;46:17-24.
27. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections. Chest 1999;115:462-74.
28. Álvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996;22:387-94.
29. Rello J, Gallego M, Mariscal D, Soñora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:196-200.
30. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262-8.
31. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676-85.
32. Weinstein MP, Towns ML, Ouartey SM, Mirrett S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology and outcome of bacteriemia and fungemia in adults. Clin Infect Dis 1997;24:584-602.
33. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244:379-86.
34. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kolleff MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55.
35. Grau S, Ferrández O. Coste de la resistencia en el ámbito hospitalario. Enferm Infecc Microbiol Clin, Monogr 2006;5:30-8.
36. Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al. Cost of gram-negative resistance. Crit Care Med 2007; 35:89-95.
37. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau D. Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006; 27:1226-32.
38. Lawrence SJ, Puzniak LA, Shadel BN, Gillespie KN, Kollef MH, Mundy LM. Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol 2007;28:123-30.
39. Álvarez-Lerma F, Grau S, Gracia-Arnillas MP. Gram-positive cocci infections in intensive care. Drugs 2006;66:751-68.
40. Zambrowski JJ. Pharmaco-économie du traitement des infections sévères en réanimation. Ann Fr Anesth Réanim 2000;19:430-5.
41. Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, De Zeeuw J, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005; 128:2238-46.
42. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004;32:137-43.
43. Kolleff MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in gram-positive ventilator associated-pneumonia: retrospective analysis of two doublé-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-94.
44. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH, Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-92.
45. Rubinstein E, Cammarata S, Oliphant T, Wunderink R, Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospital patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12.
46. Grau S, Álvarez-Lerma F, Del Castillo A, Neipp R, Rubio-Terrés C. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain. J Chemother 2005;17:203-11.